Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Philogen SpA ( (IT:PHIL) ) is now available.
Philogen S.p.A. announced an update on its share buyback program, revealing the purchase of 4,373 shares from June 30 to July 4, 2025, at an average price of Euro 21.4587 per share, totaling Euro 93,838.90. Since the program’s inception, the company has acquired 27,448 shares, representing 0.0676% of its share capital, with a total expenditure of Euro 612,402.32. This strategic move is part of Philogen’s efforts to enhance shareholder value and reflects its ongoing commitment to optimizing its capital structure.
The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR33.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.
More about Philogen SpA
Philogen is an Italian-Swiss biotechnology company focused on the research and development of pharmaceutical products targeting diseases with high mortality rates. The company specializes in creating targeted anti-cancer drugs using high-affinity ligands for tumor markers, employing technologies such as Antibody Phage Display Libraries and DNA-Encoded Chemical Libraries. Philogen’s main therapeutic strategy involves tumor targeting, which selectively delivers potent therapeutic agents to tumor masses while sparing healthy tissues. The company aims to develop and commercialize innovative treatments for diseases lacking satisfactory therapies, primarily focusing on oncological applications but also exploring potential uses for chronic inflammatory diseases.
YTD Price Performance: 7.18%
Average Trading Volume: 24,042
Technical Sentiment Signal: Buy
Current Market Cap: €611.2M
See more insights into PHIL stock on TipRanks’ Stock Analysis page.